Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BFLY NASDAQ:INMD NASDAQ:SGHT NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$4.48+2.1%$4.37$1.32▼$5.72$1.14B2.275.70 million shs3.77 million shsINMDInMode$13.89-1.0%$13.87$12.72▼$16.74$879.75M1.971.00 million shs712,885 shsSGHTSight Sciences$5.15+6.0%$4.10$3.11▼$9.24$280.16M2.38309,224 shs99,755 shsTNDMTandem Diabetes Care$15.76+4.8%$19.61$9.98▼$29.65$1.08B1.642.08 million shs994,760 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network+7.02%+11.92%-19.71%+44.16%+92.31%INMDInMode+0.25%-0.14%-3.77%-7.15%-5.01%SGHTSight Sciences+2.97%-0.82%+11.47%-11.15%+48.62%TNDMTandem Diabetes Care+8.51%+6.59%-29.19%-18.79%-36.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFLYButterfly Network$4.48+2.1%$4.37$1.32▼$5.72$1.14B2.275.70 million shs3.77 million shsINMDInMode$13.89-1.0%$13.87$12.72▼$16.74$879.75M1.971.00 million shs712,885 shsSGHTSight Sciences$5.15+6.0%$4.10$3.11▼$9.24$280.16M2.38309,224 shs99,755 shsTNDMTandem Diabetes Care$15.76+4.8%$19.61$9.98▼$29.65$1.08B1.642.08 million shs994,760 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFLYButterfly Network+7.02%+11.92%-19.71%+44.16%+92.31%INMDInMode+0.25%-0.14%-3.77%-7.15%-5.01%SGHTSight Sciences+2.97%-0.82%+11.47%-11.15%+48.62%TNDMTandem Diabetes Care+8.51%+6.59%-29.19%-18.79%-36.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFLYButterfly Network 2.33Hold$5.5624.05% UpsideINMDInMode 2.00Hold$16.0015.23% UpsideSGHTSight Sciences 2.44Hold$8.3161.41% UpsideTNDMTandem Diabetes Care 2.52Moderate Buy$29.6387.97% UpsideCurrent Analyst Ratings BreakdownLatest SGHT, BFLY, TNDM, and INMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026TNDMTandem Diabetes Care Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $25.005/11/2026TNDMTandem Diabetes Care BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold5/11/2026SGHTSight Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026TNDMTandem Diabetes Care BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$56.00 ➝ $55.005/11/2026TNDMTandem Diabetes Care Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.00 ➝ $31.005/8/2026TNDMTandem Diabetes Care MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/7/2026INMDInMode BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$21.00 ➝ $19.005/7/2026INMDInMode Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $14.005/6/2026BFLYButterfly Network Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/27/2026TNDMTandem Diabetes Care Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFLYButterfly Network$102.92M11.09N/AN/A$0.75 per share5.98INMDInMode$370.49M2.37$1.48 per share9.36$10.44 per share1.33SGHTSight Sciences$77.36M3.62N/AN/A$0.99 per share5.20TNDMTandem Diabetes Care$1.01B1.06N/AN/A$1.93 per share8.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFLYButterfly Network-$77.06M-$0.30N/AN/AN/A-73.63%-34.41%-23.91%7/31/2026 (Estimated)INMDInMode$93.83M$1.3610.21N/AN/A23.27%13.47%11.95%7/23/2026 (Estimated)SGHTSight Sciences-$38.43M-$0.71N/AN/AN/A-46.83%-52.34%-28.49%8/6/2026 (Estimated)TNDMTandem Diabetes Care-$204.71M-$1.40N/AN/AN/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)Latest SGHT, BFLY, TNDM, and INMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million5/6/2026Q1 2026INMDInMode$0.2978$0.25-$0.0478$0.18$79.84 million$82.02 million5/6/2026Q1 2026SGHTSight Sciences-$0.19-$0.24-$0.05-$0.24$18.47 million$19.70 million4/30/2026Q1 2026BFLYButterfly Network-$0.04-$0.03+$0.01-$0.05$26.08 million$26.53 million3/4/2026Q4 2025SGHTSight Sciences-$0.15-$0.08+$0.07-$0.08$20.35 million$20.39 million2/26/2026Q4 2025BFLYButterfly Network-$0.04-$0.02+$0.02-$0.06$26.25 million$31.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBFLYButterfly NetworkN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFLYButterfly NetworkN/A4.023.03INMDInModeN/A8.807.88SGHTSight Sciences0.685.865.48TNDMTandem Diabetes Care4.543.583.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFLYButterfly Network37.85%INMDInMode68.04%SGHTSight Sciences55.51%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBFLYButterfly Network25.18%INMDInMode6.92%SGHTSight Sciences30.90%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFLYButterfly Network460254.63 million190.52 millionOptionableINMDInMode48063.36 million58.98 millionOptionableSGHTSight Sciences21054.41 million37.60 millionOptionableTNDMTandem Diabetes Care2,50068.53 million67.09 millionOptionableSGHT, BFLY, TNDM, and INMD HeadlinesRecent News About These CompaniesSilver Economy Investing: Why the Healthcare Giants Are in FocusMay 19 at 4:01 PM | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Given New $25.00 Price Target at Bank of AmericaMay 19 at 3:25 AM | americanbankingnews.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 16, 2026 | americanbankingnews.comCritical Analysis: Tandem Diabetes Care (NASDAQ:TNDM) & Imris (OTCMKTS:IMRSQ)May 15, 2026 | americanbankingnews.comTandem Diabetes’s Q1 earnings call: Our top 5 analyst questionsMay 14, 2026 | msn.comTNDM stock down following Q1 earnings & revenue beat, gross margin upMay 14, 2026 | msn.comTNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin UpMay 14, 2026 | zacks.comTandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 12, 2026 | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Given "Buy" Rating at Truist FinancialMay 12, 2026 | americanbankingnews.comTandem Diabetes Care, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comTandem Diabetes Care (NASDAQ:TNDM) Receives "Buy" Rating from Truist FinancialMay 11, 2026 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 11, 2026 | finance.yahoo.comTandem Diabetes Care, Inc. $TNDM Shares Acquired by Vanguard Group Inc.May 11, 2026 | marketbeat.comTandem Diabetes Care (TNDM) Gets a Buy from Piper SandlerMay 10, 2026 | theglobeandmail.comTandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call TranscriptMay 10, 2026 | seekingalpha.comTandem Diabetes Care Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comTandem to submit tubless pump to FDA with Street-beating Q1 on record pump shipmentsMay 8, 2026 | drugdeliverybusiness.comDTandem Diabetes Care Charts Growth Amid TransitionMay 8, 2026 | tipranks.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Earnings BeatMay 8, 2026 | marketbeat.comTNDM Q1 deep dive: Margin expansion and pipeline advances amid business model shiftMay 8, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSGHT, BFLY, TNDM, and INMD Company DescriptionsButterfly Network NYSE:BFLY$4.48 +0.09 (+2.14%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.InMode NASDAQ:INMD$13.88 -0.14 (-0.96%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.Sight Sciences NASDAQ:SGHT$5.15 +0.29 (+5.97%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Tandem Diabetes Care NASDAQ:TNDM$15.76 +0.72 (+4.81%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
